New Medicines of 2015
Praluent is a prescription drug used to lower cholesterol in certain patients. Praluent belongs to a new class of drugs called proprotein convertase subtilisin kexin type 9 inhibitors, or PCSK9 inhibitors. These drugs work by blocking a naturally-occurring protein called PCSK9 to help remove LDL (bad cholesterol) cholesterol from the blood. Praluent is typically injected under the skin once every two weeks. Common side effects include itching, swelling and pain at the injection site. Praluent is a first-of-its-kind cholesterol lowering medication.
Reviewed by:
Review Date:
December 29, 2015Citation:
U.S. Food and Drug Administration, "FDA approves first-of-its-kind product for the treatment of melanoma", 2015 U.S. Food and Drug Administration, "FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa", 2015 U.S. Food and Drug Administration, "FDA approves Ninlaro, new oral medication to treat multiple myeloma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for HIV", 2015 U.S. Food and Drug Administration, "FDA approves Nucala to treat severe asthma", 2015 U.S. Food and Drug Administration, "FDA approves new treatment for advanced pancreatic cancer", 2015 U.S. Food and Drug Administration, "FDA approves first treatment for sexual desire disorder", 2015 U.S. Food and Drug Administration, "FDA approves new drug to treat heart failure", 2015 U.S. Food and Drug Administration, "FDA approves Praluent to treat certain patients with high cholesterol", 2015 U.S. Food and Drug Administration, "FDA approves Corlanor to treat heart failure", 2015 All images appear courtesy of Dreamstime
Last Updated:
December 29, 2015